Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis

被引：0
|
作者：
Noriyoshi Miura
Keiichiro Mori
Hadi Mostafaei
Fahad Quhal
Reza Sari Motlagh
Mohammad Abufaraj
Benjamin Pradere
Abdulmajeed Aydh
Ekaterina Laukhtina
David D’Andrea
Takashi Saika
Shahrokh F. Shariat
机构：
[1] Comprehensive Cancer Center,Department of Urology
[2] Medical University of Vienna,Department of Urology
[3] Ehime University Graduate School of Medicine,Department of Urology
[4] The Jikei University School of Medicine,Research Center for Evidence based Medicine
[5] Tabriz University of Medical Sciences,Department of Urology
[6] King Fahad Specialist Hospital,Division of Urology, Department of Special Surgery, Jordan University Hospital
[7] The University of Jordan,Department of Urology
[8] University Hospital of Tours,Institute for Urology and Reproductive Health
[9] King Faisal Medical City,Department of Urology
[10] Sechenov University,Department of Urology
[11] Weill Cornell Medical College,Department of Urology, Second Faculty of Medicine
[12] University of Texas Southwestern,undefined
[13] Karl Landsteiner Institute of Urology and Andrology,undefined
[14] Charles University,undefined
[15] European Association of Urology Research Foundation,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Prostate cancer; Testosterone; Meta-analysis; Androgen receptor-targeted agents; Castration-resistant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1881 / 1891
页数：10
相关论文
共 50 条
  • [41] Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis
    Zheng, Yang
    Wang, Kai
    Ou, Yong
    Hu, Xu
    Wang, Ziyan
    Wang, Dong
    Li, Xinglan
    Ren, Shangqing
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (04) : 604 - 613
  • [42] Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
    Mori, Keiichiro
    Mostafaei, Hadi
    Pradere, Benjamin
    Motlagh, Reza Sari
    Quhal, Fahad
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    Abufaraj, Mohammad
    Karakiewicz, Pierre I.
    Kimura, Takahiro
    Egawa, Shin
    Shariat, Shahrokh F.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (11) : 1892 - 1900
  • [43] Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Dwivedi, Sada Nand
    Bal, Chandrasekhar
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) : 275 - 285
  • [44] Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer A systematic review and meta-analysis of randomized controlled trials
    Zheng, Xiaonan
    Zhao, Xiaohui
    Xu, Hang
    Han, Xin
    Xu, He
    Dong, Xin
    Peng, Ruilin
    Yang, Lu
    Wei, Qiang
    Ai, Jianzhong
    MEDICINE, 2019, 98 (44) : e17748
  • [45] Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials
    Iannantuono, Giovanni Maria
    Chandran, Elias
    Floudas, Charalampos S.
    Choo-Wosoba, Hyoyoung
    Butera, Gisela
    Roselli, Mario
    Gulley, James L.
    Karzai, Fatima
    CANCER TREATMENT REVIEWS, 2023, 120
  • [46] Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
    Ternov, Klara Kvorning
    Nolsoe, Alexander Bjorneboe
    Bratt, Ola
    Fode, Mikkel
    Lindberg, Henriette
    Kistorp, Caroline
    Palapattu, Ganesh
    Klausen, Tobias Wirenfeldt
    Sonksen, Jens
    ostergren, Peter Busch
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 948 - 961
  • [47] Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
    Klara Kvorning Ternov
    Alexander Bjørneboe Nolsøe
    Ola Bratt
    Mikkel Fode
    Henriette Lindberg
    Caroline Kistorp
    Ganesh Palapattu
    Tobias Wirenfeldt Klausen
    Jens Sønksen
    Peter Busch Østergren
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 948 - 961
  • [48] Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
    Wang, Xin
    Yang, Hui
    Hu, Xiaopeng
    Wang, Wei
    Yu, Xiaojia
    Wang, Shihui
    Zhang, Xiaodong
    Liu, Lihong
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 614 - 622
  • [49] Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel
    Fujiwara, Shinnosuke
    Kosaka, Takeo
    Nishimoto, Yoshinori
    Kamisawa, Ken
    Watanabe, Keitaro
    Baba, Yuto
    Takeda, Toshikazu
    Matsumoto, Kazuhiro
    Oya, Mototsugu
    PROSTATE, 2024, 84 (01): : 25 - 31
  • [50] Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
    Wei, ZhenHeng
    Chen, ChuXin
    Li, BoWen
    Li, YongYue
    Gu, Hong
    FRONTIERS IN ONCOLOGY, 2021, 11
12345